Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 12, 2016

View Archived Issues

Japan Tobacco, Torii and Menlo enter serlopitant license agreement

KalVista initiates first-in-human trial of KVD-818 for the treatment of hereditary angioedema

Vedanta and NYU Langone to develop microbiome-derived immunotherapies for cancer

Targeting the parasite proteosome shows promise for the treatment of kinetoplastid infections

Ascendis initiates phase III registration trial for TransCon growth hormone

Bayer Pharma patents mitotic checkpoint serine/threonine-protein kinase BUB1 inhibitors

Polyphor and Gilead enter macrocycle drug discovery collaboration

Novogen submits IND to FDA for cantrixil

VAL-401 receives regulatory approval for phase IIb clinical trial in Georgia

Resverlogix will continue phase III trial testing apabetalone based on DSMB recommendation

Medshine Discovery discloses JAK inhibitors

MedImmune develops TB4 fusion polypeptides

Mallinckrodt to acquire Stratatech Corporation

Wockhardt reports beta-lactamase inhibitors

Inovio Pharmaceuticals doubles enrollment for its phase I trial of Ebola vaccine

Zealand Pharma reports results from phase II trial of dasiglucagon

Acacia Pharma announces pivotal phase III results of Baremsis for the treatment of PONV

Zymeworks begins research collaboration with Innovative Targeting Solutions

Targeting astroglial NF-kappaB signaling as a novel treatment option for vascular dementia

BioCryst Pharmaceuticals doses first subject in phase II trial of BCX-7353

Epizyme doses first patient in phase II trial of tazemetostat

Pfizer reveals milestones of second quarter 2016

Advaxis advances phase II trial of axalimogene filolisbac to its second stage

Cryoport expands contract with Stemedica for stem cell therapies against Alzheimer's disease

Vigilant Biosciences receives phase I grant for next-generation oral cancer diagnostic test

EZH1 mutations are the second most frequent genetic alteration in ATAs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...